New York, June 25, 2012 -- Kenyon & Kenyon LLP client Teva Pharmaceuticals won consolidated Hatch-Waxman patent litigations on June 22, 2012 in Teva Pharmaceuticals USA, Inc. et al v. Mylan Pharmaceuticals Inc. et al, 1:09-cv-08824-BSJ. The litigation pertains to proposed generic equivalents to Teva's blockbuster multiple sclerosis drug Copaxone®. Following trial, the Honorable Barbara S. Jones of the Southern District of New York rejected challenges to Teva’s patents, finding that “the Defendants', Mylan Pharmaceuticals Inc., et al. and Sandoz, Inc. et al., abbreviated new drug applications infringe all of the asserted claims of the Plaintiffs' patents and that none of the asserted claims are invalid or unenforceable.” Kenyon & Kenyon LLP partner Elizabeth Holland acted as lead trial counsel representing Teva in the case. Kenyon partner William G. James also acted as trial counsel, along with attorneys from Goodwin Procter.
About Kenyon & Kenyon LLP
Kenyon & Kenyon is consistently ranked by peers and in-house counsel as one of the top firms for intellectual property law. Since its founding in 1879, the firm has provided its worldwide clientele with litigation, prosecution, licensing and counseling services. Large and small enterprises and individuals choose Kenyon to design and implement intellectual property strategies when it matters most. The firm has offices in New York, Washington, DC, and Silicon Valley.